ReviewDiscover oncology2026
MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most aggressive primary brain tumor and is associated with poor prognosis due to marked molecular heterogeneity and limited efficacy of current diagnostic and therapeutic strategies. MicroRNAs (miRNAs) have emerged as key post transcriptional regulators involved in glioblastoma progression, therapy resistance, and tumor recurrence. This review critically synthesizes recent evidence on dysregulated miRNAs in glioblastoma, with focused emphasis on their validated diagnostic and prognostic relevance. Particular attention is given to circulating miRNAs detected through minimally invasive liquid biopsy platforms, highlighting their potential to complement existing molecular markers. Rather than cataloguing isolated findings, this review prioritizes miRNAs with consistent evidence across studies and discusses their translational applicability in clinical decision making. Current limitations related to methodological variability, tumor heterogeneity, and lack of standardization are also addressed. Overall, this work provides an evidence weighted framework that clarifies the clinical promise and remaining challenges of miRNAs based biomarkers in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.